<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The present study was undertaken to ascertain the frequency of cytogenetic polyclonality in various <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> and to investigate whether morphologic subgroup, age, gender, or previous genotoxic exposure influences the incidence </plain></SENT>
<SENT sid="1" pm="."><plain>Among 2,243 cytogenetically investigated <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e>, 10 <z:hpo ids='HP_0004808'>acute myeloid leukemias</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), 5 <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), 2 <z:hpo ids='HP_0006721'>acute lymphoblastic leukemias</z:hpo> (ALL), 1 <z:hpo ids='HP_0011009'>acute</z:hpo> undifferentiated <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AUL</z:e>), 1 atypical Philadelphia chromosome-negative (Ph-) <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>), 1 <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0005547'>myeloproliferative disorder</z:hpo> (CMD), and 1 <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0005523'>lymphoproliferative disorder</z:hpo> (CLD) with karyotypically unrelated clones were identified, constituting 2.6% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, 1.6% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, 0.8% of ALL, 13% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AUL</z:e>, 9.1% of Ph- <z:mp ids='MP_0005481'>CML</z:mp>, 1.5% of CMD, and 2.8% of CLD with chromosomal abnormalities </plain></SENT>
<SENT sid="2" pm="."><plain>In contrast to the cytogenetic features, the X-inactivation pattern was monoclonal in the two informative female patients that could be investigated </plain></SENT>
<SENT sid="3" pm="."><plain>Among 17,733 karyotypically aberrant published cases surveyed, significant frequency differences (P &lt; 0.001) were discerned: 1.7% of 6,526 AML, 3.4% of 2,391 MDS, 0.4% of 1,920 Ph+ <z:mp ids='MP_0005481'>CML</z:mp>, 2.9% of 856 CMD, 0.9% of 4,226 ALL, and 5.8% of 1,814 CLD displayed unrelated clones </plain></SENT>
<SENT sid="4" pm="."><plain>The incidence of cytogenetic polyclonality did not differ significantly among the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, CMD, or ALL subgroups, between males and females, between children (&lt; 16 years) and adults, or between B- and T-cell ALL, whereas the frequencies varied among the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> FAB types (P &lt; 0.05), among the different CLD entities (P &lt; 0.001), and between B- and T-cell CLD (P &lt; 0.001) </plain></SENT>
<SENT sid="5" pm="."><plain>Furthermore, the incidence was higher in <z:e sem="disease" ids="C1292776" disease_type="Neoplastic Process" abbrv="">therapy-related AML and MDS</z:e> than in de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (P &lt; 0.001 and P &lt; 0.01, respectively) </plain></SENT>
</text></document>